Get started
Author

Sarah K. Emond

Observed names: Emond, Sarah, S. Emond, S.K. Emond, Sarah Emond, Sarah K Emond
ORCID: 0009-0007-9766-0994
Observed ORCID: 0009-0007-9766-0994
OpenAlex ID: A5061393393
Instant Vertebral Assessment
2001 · Susan L. Greenspan, Eric von Stetten, et al. · Journal of Clinical Densitometry · 130
A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women
2001 · S. L. Ferrari, P. Garnero, et al. · Arthritis & Rheumatism · 92
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US
2025 · Steven D Pearson, Christopher M Whaley, et al. · Journal of Comparative Effectiveness Research · 63
PDF
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States
2024 · Sharon Phares, Mark Trusheim, et al. · Journal of Comparative Effectiveness Research · 48
Why Do Older Women Discontinue Hormone Replacement Therapy?
2001 · Meredith M. Regan, Sarah K. Emond, et al. · Journal of Women s Health & Gender-Based Medicine · 35
Institute for Clinical and Economic Review – Peterson Health Technology Institute value assessment framework for digital health technologies
2023 · Steven D Pearson, Prabhjot Singh, et al. · Journal of Comparative Effectiveness Research · 11
Translating comparative effectiveness research into Medicaid payment policy: views from medical and pharmacy directors
2015 · Joel S Weissman, Kimberly Westrich, et al. · Journal of Comparative Effectiveness Research · 11
Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability
2025 · Sarah K. Emond, Wim G. Goettsch, et al. · Clinical Pharmacology & Therapeutics · 6
PDF
Evaluating the Evidence on Comparative Effectiveness and Value of Management Options for Treatment-Resistant Depression
2013 · Sarah K. Emond, Daniel A. Ollendorf, et al. · Postgraduate Medicine · 5
Management Strategies for Attention–Deficit/Hyperactivity Disorder: A Regional Deliberation on the Evidence
2012 · Sarah K. Emond, Daniel A. Ollendorf, et al. · Postgraduate Medicine · 2
Institute for Clinical and Economic Review's role in the US health care system: Centering the patient perspective
2025 · Sarah K Emond, Catherine K Fischer · Health Affairs Scholar · 1
PDF
Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch
2024 · Marina Richardson, Abigail C. Wright, et al. · Value in Health · 1
PDF
P3 An Assessment of Barriers to Fair Access to Cost-Effective Drugs
2022 · M. Beinfeld, S.K. Emond, et al. · Value in Health · 1
PDF
ICER's launch price and access report: 5 key takeaways and 5 questions we should all be asking
2026 · Foluso Agboola, Sarah K Emond · Health Affairs Scholar
How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients
2025 · Sarah K Emond, Daniel A Ollendorf · Health Affairs Scholar
PDF
Walking a fine line. Comparative effectiveness panel must handle tricky issues of value, innovation.
2010 · Sarah Emond, Valerie Fleishman · PubMed
Works count: 17
Citation count: 406
H-index: 7
I10-index: 7
Year
Topic
Type